US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. June 24, 2019

    Drugmakers' Emails, Calls Show Price-Fix Coverup, AGs Say

    Unredacted emails and phone records show Teva Pharmaceuticals, Pfizer Inc. and 18 other major U.S. drug manufacturers conspiring in an industrywide price-fixing scheme to keep the cost of hundreds of generic drugs artificially high, according to a complaint unsealed Monday by the Maryland attorney general's office.

  2. June 07, 2019

    States Call For Unredacting Of Their Generic-Drug Pricing Suit

    The attorneys general of 44 states and Puerto Rico want a Pennsylvania federal judge to make public an unredacted version of their suit accusing major drugmakers of orchestrating a sprawling scheme to fix the price of generics, saying the suit's subject matter was of "paramount public significance."

  3. June 04, 2019

    44 States' Generic-Drug Pricing Suit Rolled Into Pa. MDL

    A lawsuit filed in Connecticut last month by 44 state attorneys general accusing drugmakers of a sprawling scheme to fix generic-drug prices was transferred Tuesday to the Pennsylvania federal court overseeing multidistrict litigation over pricing in the industry.

  4. June 03, 2019

    Drugmakers Want AGs' Generics Price-Fixing Claims Tossed

    Pharmaceutical companies including Actavis, Teva and Mylan have asked a Pennsylvania federal court to dismiss state law claims by 47 state attorneys general against them in multidistrict litigation accusing them of price-fixing generic drugs.

  5. May 16, 2019

    United, Humana Say Classes Can't Carve Up Generic Awards

    United Healthcare and Humana want the Pennsylvania federal court overseeing sprawling multidistrict litigation over generic drug prices to refuse to grant an order that would set aside part of any money the health care companies might win for the main class.

  6. April 12, 2019

    Judge Won't Certify Perrigo's Appeal In Drug Price-Fixing MDL

    A Pennsylvania federal judge on Thursday refused to certify an interlocutory appeal from pharmaceutical company Perrigo on claims related to one drug in sprawling price-fixing multidistrict litigation, noting that even if the company's appeal goes through, it must still face claims related to other medications.

  7. February 19, 2019

    Generics Cos. To Face Most State Claims In Price-Fixing MDL

    A Pennsylvania federal judge has largely refused to cull state law claims accusing numerous generic-drug makers of conspiring to fix prices, with only a handful of claims nixed from the massive multidistrict litigation on technical grounds.

  8. February 01, 2019

    AGs Want To Unlock Redacted Generic Price-Fixing Complaint

    A group of state attorneys general and others accusing generic-drug makers of conspiring to fix prices for their products told a Pennsylvania federal judge on Friday that the public importance of the litigation warranted their previously redacted complaint being unsealed in full.

  9. January 04, 2019

    Judge Won't Gag AGs In Generics Price-Fixing Case

    A Pennsylvania federal judge on Friday denied a bid by generic-drug makers to win a court order that would limit what the state attorneys general accusing the companies of price fixing can say publicly about their investigation and the multidistrict litigation over the alleged conduct.

  10. January 03, 2019

    AGs Blast Generic Cos.' Bid To Gag Price-Fixing Comments

    Defending their right to comment publicly on multidistrict litigation and ongoing probes into alleged price-fixing by generic-drug companies, dozens of state attorneys general have told a Pennsylvania federal judge that a speech limitation sought by the drug companies would be unnecessary and unconstitutional.